Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BMS’s Revlimid Loss Of Exclusivity Is Not As Bad As Expected, But Not For Long

Apr 29 2022

• By Alaric DeArment

earnings report — BMS announced its first quarter earnings on 29 April • Source: Shutterstock

Related Content

Merck & Co.'s Solid Growth Turbo-Charged By Lagevrio For COVID-19

Apr 28 2022

Gilead Sees HIV Business Return To Sales Growth As Oncology Gets Boost

Apr 28 2022

Merck Jumps Into Lucrative Adjuvant NSCLC Space With Keytruda Data

Mar 18 2022

BMS Wins Competition For Novel Checkpoint Inhibitors With Relatlimab Approval

Mar 21 2022

Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames

Apr 15 2022

BMS Gets First Immunotherapy Approval In Neoadjuvant Lung Cancer, Quickly

Mar 07 2022

BMS Projects 2022 Growth Even With $3bn Hit From Revlimid, Abraxane Generics

Jan 11 2022

Related Companies

Bristol Myers Squibb Company

Johnson & Johnson

Novartis AG

Gilead Sciences, Inc.

Merck & Co., Inc.

Nektar Therapeutics

Additional Topics

Companies Sales & Earnings Business Strategies Commercial BioPharmaceutical

More from Business

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window